OyaGen

OyaGen is a biotech focused on drug discovery for HIV. We are internationally recognized for a novel target for first in class therapy with curative potential.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Rochester, NY, US
  • Currency USD
  • Founded May 2003
  • Employees 6
  • Website oyageninc.com

Company Summary

We are 12-18 months from filing an IND on a first in class HIV therapeutic that may well have curative capability. OyaGen's platform technology will enable several new drug developments for HIV targets and enables future pursuit of new drugs for cancer, Ebola and areas with cannabis. Our business model is to develop novel therapeutics ready for partnering.

see: www.oyageninc.com & http://en.wikipedia.org/wiki/OyaGen

Team

  • Harold Smith
    Founder CEO and President

    Over 35 years in biomedical research and discovery. Full Professor at the University of Rochester School of Medicine and Dentistry

Advisors

  • Richard Ogden
    Preclinical Development Advisory Board
    Dr. Richard McCloskey
    Board of Directors
    Unconfirmed
    Dr. Roscoe Moore, Ret USA Assistant Surgeon General
    Board of Directors
    Unconfirmed
  • Dr. David Ho
    Scientific Advisory Board
    Unconfirmed
    Dr. Mansukh Wani
    Scientific Advisory Board
    Unconfirmed
    Tom Chung
    Scientific Advisory Board
  • Dr. Robert Buckheit
    Scientific Advisory Board
    Unconfirmed
    Harold Smith
    Founder, CEO and PResident

Previous Investors

  • Kevin Phelps
    Trillium Group, Rochester NY
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free